Glucagon‐like peptide‐1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and the risk of bone fracture in patients with type 2 diabetes mellitus (T2DM). Materials and methods: We conducted a systematic literature search in PubMed, Embase, the Cochrane Library, and Web of Science from inception to 28 February 2018 and identified eligible randomized controlled trials. The following data were extracted from each study: first author, year of publication, sample size, patient characteristics, study design, intervention drug, control drug, follow‐up time, and incident bone fracture events. A meta‐analysis was conducted using Review Manager 5.3 software to calculate the odds ratio (OR) and 95% confidence intervals (CI) for dichotomous variables. Results: A total of 38 studies with 39 795 patients with T2DM were included. There were 241 incident bone fracture cases (107 in the GLP‐1 RAs group and 134 in the control group). Compared with patients who received placebo and other anti‐diabetic drugs, those who received GLP‐1 RAs treatment showed a pooled OR of 0.71 (95% CI, 0.56‐0.91) for bone fracture. Subgroup analysis showed that treatments with liraglutide and lixisenatide were associated with significantly reduced risk of bone fractures (ORs, 0.56; 95% CI, 0.38‐0.81 and 0.55; 95% CI, 0.31‐0.97, respectively). However, other GLP‐1 RAs did not show superiority to placebo or other anti‐diabetic drugs. Moreover, these beneficial effects were dependent on the duration of GLP‐1 RAs treatment, only a GLP‐1 RAs treatment period of more than 52 weeks could significantly lower the risk of bone fracture in patients with T2DM (OR, 0.71; 95% CI, 0.56‐0.91). Conclusions: Compared with placebo and other anti‐diabetic drugs, liraglutide and lixisenatide were associated with a significant reduction in the risk of bone fractures, and the beneficial effects were dependent on the duration of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“Liraglutide, compared with exenatide, was associated with greater improvement in glycemic control and less frequent hypoglycemia.(18) Although similar in glycemic control, a lower incidence of hypoglycemia was also observed with lixisenatide than with exenatide.”
BackgroundMechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253 · cited 1×
“Although similar in glycemic control, a lower incidence of hypoglycemia was also observed with lixisenatide than with exenatide.(19) Hypoglycemia and poor glycemic control were associated with an increased risk of fractures, which might be due to the increased risk of fall and the adverse effects on bone metabolism.”
BackgroundMa, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200 · cited 1×
“It was reported that GLP‐1 RAs bound to the GLP‐1 receptor on bone cells, which increased the number of osteoblasts, promoted the expression of genes related to bone formation, and increased the levels of bone formation factors.(28,29) Second, GLP‐1 RAs inhibited bone resorption.”
BackgroundIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193 · cited 1×
“Although many clinical trials and observational studies investigated the association between bone fracture and GLP‐1 RAs, the results are inconsistent.(15,16) Therefore, we conducted a meta‐analysis to assess and compare the fracture risk in patients withT2DM treated with GLP‐1 RAs, and those receiving placebo or othe…”
ResultDriessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79 · cited 1×
“Although many clinical trials and observational studies investigated the association between bone fracture and GLP‐1 RAs, the results are inconsistent.(15,16) Therefore, we conducted a meta‐analysis to assess and compare the fracture risk in patients withT2DM treated with GLP‐1 RAs, and those receiving placebo or othe…”
ResultSafety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Research works printed but not linked: 22
- 10.1016/j.lpm.2013.02.313 · DOI
- 10.18632/oncotarget.23937 · doi:10.18632/oncotarget.23937
- 10.1002/jbmr.3435 · DOI
- 10.2147/TCRM.S131945 · DOI · Paper page
- 10.1007/s11914-015-0265-0 · DOI
- 10.1016/j.cca.2006.03.017 · DOI
- 10.3389/fendo.2018.00006 · DOI · Paper page
- 10.1007/s00198-017-4096-y · DOI
- 10.1016/j.ecl.2013.06.005 · DOI
- 10.1146/annurev-physiol-021113-170315 · DOI · Paper page
- 10.1007/s40618-014-0137-y · DOI
- 10.3389/fendo.2017.00098 · DOI · Paper page
- GentilellaR PechtnerV CorcosA ConsoliA.Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?2018;35(1):e3070.https://doi.org/10.1002/dmrr.3070 · DOI · Paper page
- 10.1016/j.jdiacomp.2018.04.005 · DOI
- 10.1016/j.diabres.2016.03.009 · DOI · Paper page
- 10.1007/s00198-017-4021-4 · DOI
- 10.1016/S0140-6736(12)61267-7 · DOI · Paper page
- 10.1111/1753-0407.12372 · DOI
- 10.1007/s00774-018-0960-x · DOI
- Dubey A, 2000, The effects of diabetes on outcome after hip fracture, Bull Hosp Jt Dis, 59, 94
- 10.1155/2012/519784 · DOI
- 10.1016/j.stemcr.2016.02.002 · DOI · Paper page
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Ebeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 338
Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus
Khosla, S., Samakkarnthai, P., Monroe, D. G., & Farr, J. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00555-5 · Cited by 260
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
Metadata
- Authors
- Cheng, L., Hu, Y., Li, Y., Cao, X., Bai, N., Lu, T., Li, G., Li, N., Wang, A., & Mao, X.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2019-05-06
- Volume
- 35
- Issue
- 7
- Pages
- e3168-e3168
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2937718630
- Cited by
- 111
- References
- 8
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.